Clinical Trial

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 6, 2023 (before its estimated July 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a single center, open, single arm, dose increasing early clinical study. The purpose of this study is to evaluate the safety and efficacy of YK0901 immunotherapy in the treatment of patients with advanced solid tumor whose tumor antigen KRAS G12V expression is positive (HLA-A \* 11:01).
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05933668
Lead Sponsor Peking University
Collaborators: Yingkai Saiwei（Beijing）Biotechnology Co., Ltd
Conditions Advanced Solid Tumor
Enrollment 11 participants
Start Date 2023-07
Primary Completion 2024-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2023-07-06